Titre :

Omalizumab drug survival in chronic urticaria: a retrospective multicentric French study.

Auteur(s) :

Litovsky, Julie [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Hacard, Florence [Auteur]
Hospices Civils de Lyon [HCL]
Tetart, Florence [Auteur]
CHU Rouen
Boccon-Gibod, Isabelle [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Soria, Angèle [Auteur]
CHU Tenon [AP-HP]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Doutre, Marie-Sylvie [Auteur]
Hôpital Saint-André [Bordeaux]
Amsler, Emmanuelle [Auteur]
CHU Tenon [AP-HP]
Mansard, Catherine [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Dezoteux, Frédéric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Milpied, Brigitte [Auteur]
Hôpital Saint-André
Bernier, Claire [Auteur]
Hôtel-Dieu de Nantes
Perrot, Jean-Luc [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Raison-Peyron, Nadia [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Paryl, Marie [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Droitcourt, Catherine [Auteur]
École des Hautes Études en Santé Publique [EHESP] [EHESP]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Demoly, Pascal [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Grosjean, Julien [Auteur]
CHU Rouen
Mura, Thibault [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Du-Thanh, Aurélie [Auteur]
CHU Montpellier = Montpellier University Hospital

Titre de la revue :

Journal of Allergy and Clinical Immunology: In Practice

Nom court de la revue :

J Allergy Clin Immunol Pract

Date de publication :

2023-09-05

ISSN :

2213-2201

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background: Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU).Objective: We aimed to evaluate the discontinuation patterns of OMA and their determinants in ...
Lire la suite >Background: Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU).Objective: We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU.Methods: We conducted a retrospective multicenter study in 9 French tertiary referral hospitals. All patients diagnosed with either spontaneous (CSU) and/or inducible (CIndU) CU who received at least 1 injection of OMA between 2009 and 2021 were included. We analyzed OMA drug survival and investigated possible determinants using Kaplan-Meier curves and log-rank tests.Results: A total of 878 patients were included in this study; 48.8% had CSU, 10.1% CIndU, and 41.1% a combination of both. OMA was discontinued in 408 patients, but the drug was later reintroduced in 50% of them. The main reason for discontinuing treatment was the achievement of a well-controlled disease in 50% of patients. Half of the patients were still being treated with OMA 2.4 years after the initiation of treatment. Drug survival was shorter in patients with CIndU and in those with an autoimmune background. In atopic patients, OMA was discontinued earlier in patients achieving a well-controlled disease. A longer OMA drug survival was observed in patients with a longer disease duration at initiation.Conclusion: In French patients with CU, the drug survival of OMA appears to be longer than that observed in previous studies conducted elsewhere, highlighting discrepancies in prescription and reimbursement possibilities. Further studies are warranted to develop customized OMA treatment schemes based on individual patterns.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T22:17:38Z
2024-03-07T12:21:40Z